Results 201 to 210 of about 50,167 (231)

Hotspots and Emerging Trends in JAK Inhibitor Therapy for Vitiligo: A Bibliometric Analysis (2015-2025). [PDF]

J Inflamm Res
Peng Y, Feng J, Lu L, He H, Xie A, Zhang S, Yang L, Liu Y, Wang T.   +8 more
europepmc   +1 more source

Trajectory of lipid profiles in rheumatoid arthritis patients receiving tofacitinib: Evidence from the prospective CENTRA cohort. [PDF]

Br J Clin Pharmacol
Huang H, Geng Y, Fan Y, Zhao J, Zhang Z.
europepmc   +1 more source

Comparative treatment persistence of upadacitinib vs. tofacitinib in psoriatic arthritis: a multicenter observational study from the BIRRA cohort. [PDF]

Front Med (Lausanne)
Conforti A, Gentile M, Cipolloni V, Lucchetti L, Priora M, Becciolini A, Celletti E, Penta MD, Lo Gullo A, Paroli M, Bravi E, Andracco R, Nucera V, Ometto F, Lumetti F, Farina A, Colina M, Ravagnani V, Scolieri P, Larosa M, Visalli E, Addimanda O, Vitetta R, Volpe A, Bezzi A, Girelli F, Colella ABM, Caccavale R, Donato ED, Adorni G, Santilli D, Lucchini G, Arrigoni E, Sabatini E, Platè I, Mansueto N, Ianniello A, Fusaro E, Ditto MC, Bruzzese V, Camellino D, Bianchi G, Serale F, Foti R, Amato G, Lucia F, Bosco YD, Foti R, Reta M, Fiorenza A, Rovera G, Marchetta A, Focherini MC, Mascella F, Bernardi S, Sandri G, Giuggioli D, Salvarani C, Franchina V, Colella FM, Ferrero G, Magnani M, Maset M, Mazzanti C, Santoboni G, Angrisani C, Simone M, Raffeiner B, Parisi S, Ariani A.   +69 more
europepmc   +1 more source

Identification of Pyrrolo [2,3-<i>b</i>] Pyridine Derivatives as Novel JAK1 Inhibitors for the Treatment of Inflammatory Bowel Disease. [PDF]

Molecules
Wen S, Xiao C, Du LM, Ji J, Sha HK, Lin SX, Mou Y, Sun H, Jiang ZY.   +8 more
europepmc   +1 more source

Emerging and Investigational JAK Inhibitors for Rheumatoid Arthritis: Efficacy and Safety. [PDF]

Drug Des Devel Ther
Costa L, Caso F, Maione F, Giacomelli R, Ruscitti P.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tofacitinib

Reactions Weekly
  +17 more sources

Tofacitinib

Reactions Weekly, 2023
  +7 more sources

Tofacitinib

Reactions Weekly, 2021
  +4 more sources

Tofacitinib

Reactions Weekly, 2020
  +4 more sources